EUCTR2010-023923-78-AT进行中（未招募）不适用
A prospective clinical trial to evaluate the V4 Drug delivery device for long term delivery of Ranibizumab for the Treatment of Choroidal Neovascularization” - Drug Delivery Device for Long Term Delivery of Ranibizumab for the Treatment of Choroidal Neovascula
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male and female patients at least 50 years of age who meet the following entry criteria will be eligible for enrollment in this study: 1. Diagnosis of CNV secondary to AMD confirmed by fluorescein angiography, not previously treated, and for which anti-VEGF intraocular injection is indicated (>25% active disease with <75% of the lesion size representing scar, pigment epithelial detachment, blood or atrophy). 2. Retinal thickness due to edema of at least 300µm in study eye 3. Not eligible for laser treatment 4. Best corrected visual acuity of 20/50 or worse in the eye to be treated 5. Best corrected visual acuity of 20/40 or better in the fellow eye 6. Good visibility of macular area on biomicroscopy 7. Capable of understanding the requirements of the study willing to follow study instructions, to provide written informed consent to participate, and who agree to comply with all study requirements, including the required study follow-up visits.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with the following characteristics will be excluded from the study: 1. Evidence of scarring CNV (e.g. geographic atrophy) in the study eye 2. Fibrosis =75% of lesion area in the study eye 3. Vision better than 20/50 in the study eye 4. Any ophthalmic surgery performed on the study eye within three (3) months prior to study 5. Any prior treatment with an anti-VEGF agent (i.e. Lucentis, Avastin, Macugen, VEGF Trap-Eye) in the study eye 6. Prior vitrectomy in the study eye 7. Any previous or current retinal vascular disease in the study eye 8. Myopia > -6D 9. Clinically significant inflammation or infection within six (6) months prior to study. 10. Use of anticoagulant or antiplatelet therapy other than aspirin and non-steroidal anti-inflammatory agents (NSAID) within 14 days of enrollment 11. Presence of non-healing wound, ulcer, fracture or any medical condition associated with bleeding 12. Use of antimitotic or antimetabolite therapy within 30 days or 5 elimination half-lives of enrollment 13. History of stroke or myocardial infraction or other high risk patients for cardiovascular or cerebrovascular disease (package insert of Lucentis) 14. Glaucoma or ocular hypertension 15. Uncontrolled systemic disease (e.g., diabetes, hypertension, etc.) that in the opinion of the investigator could confound the study outcomes or prevent the patient from completing the study 16. Participation in any study involving an investigational drug within the past 30 calendar days, or ongoing participation in a study with an investigational product. 17. Intolerance or hypersensitivity to topical anesthetics, mydriatics, any of the excipients in Lucentis, fluorescein or components of the drug delivery device 18. A medical condition, serious concurrent illness, or extenuating circumstance that would significantly decrease study compliance, including all prescribed follow-up 19. Any condition that, in the opinion of the investigator, would jeopardize the safety of the patient.
研究者
相似试验
进行中（未招募）
1 期
Prospective Phase IV Clinical Trial on Effectiveness of Rebif Treatment of CIS and RMS Patients in Romania using Electronic Device RebiSmart™EUCTR2014-001290-14-ROMERCK ROMANIA SR
已完成
不适用
Clinical study to evaluate the efficacy of a new vitamin D derivative to the patients with a long history of bisphosphonate treatmentOsteoporosisJPRN-UMIN000009495Dept. of Orthopedic Surgery, Keio Univesity, School of Medicine120
招募中
1 期
Multicentre Phase IV clinical trial to evaluate the efficacy of hyperthermic intraoperative chemotherapy (HIPEC) with Mitomycin-C after complete surgical debulking in patients with peritoneal metastases of colon cancer.peritoneal metastases of colorectal cancerCTIS2024-512726-28-00Hospital Universitario De Fuenlabrada216
进行中（未招募）
1 期
Phase 4 clinical trial to evaluate the effect on immune recovery of antiretroviral treatment of three drugs versus two in in HIV-infected patients but not dectactable in blood.Adult patients with HIV infection on stable therapy (= 6 months) with triple therapy and undetectable viremia for = 1 year.MedDRA version: 19.1Level: LLTClassification code 10049838Term: HIV viral load undetectableSystem Organ Class: 100000004848MedDRA version: 19.1Level: PTClassification code 10077716Term: HIV viraemiaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-005226-11-ESFundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI)180
已完成
不适用
Effect of Virechanakarma (Purgation therapy) in males having altered lipid levels in blood pertaining to Lingayat communityCTRI/2013/10/004094IGIB New Delhi7